Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Germonpre

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Expert Review of Anticancer Therapy|August 30, 2013
Antineoplastic therapy-induced pulmonary toxicityAnna M Sadowska, Pol Specenier, Paul Germonpre, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2009
Endobronchial lipomas: rare benign lung tumors, two case reportsChristophe Pollefliet, Kevin Peters, Annelies Janssens, et al.
Translational Lung Cancer Research|March 26, 2015
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome itChristian Rolfo, Francesco Passiglia, Marta Castiglia, et al.
Cancer Treatment Reviews|June 24, 2014
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsChristian Rolfo, Elisa Giovannetti, David S Hong, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Expert Review of Anticancer Therapy|August 30, 2013
Antineoplastic therapy-induced pulmonary toxicityAnna M Sadowska, Pol Specenier, Paul Germonpre, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2009
Endobronchial lipomas: rare benign lung tumors, two case reportsChristophe Pollefliet, Kevin Peters, Annelies Janssens, et al.
Translational Lung Cancer Research|March 26, 2015
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome itChristian Rolfo, Francesco Passiglia, Marta Castiglia, et al.
Cancer Treatment Reviews|June 24, 2014
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsChristian Rolfo, Elisa Giovannetti, David S Hong, et al.
Pageof 1